Furthermore, there is solid evidence that the use of a GnRH antagonist is associated with a substantial reduction in ovarian hyperstimulation syndrome (OHSS) risk compared with long-course GnRH agonist protocols (3), without reducing the likelihood of achieving live birth (4). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.